Quantum BioPharma

04/08/2026

3rd Party Article :
Quantum Biopharma seeks FDA clearance to test Lucid-MS in patients

Phase 2 trial will assess if therapy can stop demyelination and slow MS

Written by Andrea Lobo, PhD | April 2, 2026

https://multiplesclerosisnewstoday.com/news-posts/2026/04/02/quantum-biopharma-asks-fda-clear-phase-2-trial-lucid-ms

Quantum Biopharma has filed with the FDA to start a Phase 2 trial of Lucid-MS to assess the treatment's ability to halt disease progression.

04/02/2026

Quantum BioPharma Wins Significant Court Challenge in USD $700,000,000 Claim as Defendants Joint Motion to Dismiss Lawsuit Alleging Market Manipulation by CIBC World Markets and RBC Dominion Securities is Denied

https://www.globenewswire.com/news-release/2026/04/02/3267341/0/en/Quantum-BioPharma-Wins-Significant-Court-Challenge-in-USD-700-000-000-Claim-as-Defendants-Joint-Motion-to-Dismiss-Lawsuit-Alleging-Market-Manipulation-by-CIBC-World-Markets-and-RBC.html

$QNTM

04/01/2026

Quantum BioPharma Submits Investigational New Drug (IND) Application to United States Food and Drug Administration (FDA) for Lucid-MS Phase Two Clinical Trial in Multiple Sclerosis

https://www.globenewswire.com/news-release/2026/04/01/3266579/0/en/Quantum-BioPharma-Submits-Investigational-New-Drug-IND-Application-to-United-States-Food-and-Drug-Administration-FDA-for-Lucid-MS-Phase-Two-Clinical-Trial-in-Multiple-Sclerosis.html

$QNTM

03/30/2026

Quantum BioPharma Signs Binding Letter Of Intent With Allucent To Conduct Phase 2 Clinical Trial In Multiple Sclerosis

Strategic Partnership with Global Clinical Research Organization (CRO) Signifies Advancement in Clinical Development of Lucid-21-302 (Lucid-MS), a Novel First-in-Class Treatment Inhibiting Demyelination

https://www.globenewswire.com/news-release/2026/03/30/3264540/0/en/Quantum-BioPharma-Signs-Binding-Letter-Of-Intent-With-Allucent-To-Conduct-Phase-2-Clinical-Trial-In-Multiple-Sclerosis.html

$QNTM

03/27/2026

Quantum Biopharma’s 2025 Audited Year End Financial Results Maintain ‘No Going Concern’ Status

Financial Statements as of Date of Filing Show Strong Improvements in Cash, Reduction in Accounts Payable, and a Cash Runway Through January 2028

https://www.globenewswire.com/news-release/2026/03/27/3263740/0/en/Quantum-Biopharma-s-2025-Audited-Year-End-Financial-Results-Maintain-No-Going-Concern-Status.html

$QNTM

03/26/2026

Breaking News:
Quantum Biopharma Announces Appointment of Principal Investigator for Planned Phase 2 Clinical Trial of Lucid-21-302 (Lucid-MS) in Multiple Sclerosis

Highlights advancement of first-in-class neuroprotective candidate targeting demyelination

https://www.globenewswire.com/news-release/2026/03/26/3262941/0/en/Quantum-Biopharma-Announces-Appointment-of-Principal-Investigator-for-Planned-Phase-2-Clinical-Trial-of-Lucid-21-302-Lucid-MS-in-Multiple-Sclerosis.html

$QNTM

03/23/2026

The peer-reviewed publication is now publicly available and can be accessed here:

https://zenodo.org/records/18873638

03/23/2026

Quantum BioPharma Announces Peer-Reviewed Journal Publication of Groundbreaking Clinical Trial With Unbuzzd (Unbuzzd wellness)

unbuzzd Dramatically Accelerates Alcohol Metabolism, Speeds the Reduction of Blood Alcohol Concentration, and Reduces Symptoms of Intoxication, Impairment and Hangover



https://www.globenewswire.com/news-release/2026/03/23/3260361/0/en/Quantum-BioPharma-Announces-Peer-Reviewed-Journal-Publication-of-Groundbreaking-Clinical-Trial-With-Unbuzzd.html

03/05/2026

Christina Applegate speaks candidly about her battle with Multiple Sclerosis: “I hate it.”

Thank you for using your voice to help raise awareness around the realities of living with MS.

Conversations like this matter and help bring greater visibility to patients, families, and the urgent need for continued research.

From all of us at Quantum BioPharma, we appreciate your openness and advocacy.

Christina Applegate sits down with Robin Roberts to talk about her new memoir "You With the Sad Eyes."

03/03/2026

Thank you National MS Society and to all those affected by Multiple Sclerosis — patients, families, caregivers, researchers, and advocates.

Your strength, commitment, and ongoing efforts continue to advance awareness and progress.

02/10/2026

From an MS patient’s perspective, this is unsettling.

In this clip, I talk with the team at Quantum BioPharma about claims of market interference that they say affected funding and slowed progress on a drug designed to help people living with MS.

It is a rare look at how financial pressures can impact scientific progress and the patients waiting for answers.

02/10/2026

What happens when illegal market activity collides with medical research?

In this clip, I talk with the team at Quantum BioPharma about alleged stock spoofing and market activity that the company says interfered with their ability to fund and advance a promising MS drug.

It is a rare look at how financial misconduct can directly impact scientific progress and patients waiting for answers.